China Resources Double-Crane Pharmaceutical (SHA:600062) controlling subsidiary Double-Crane Xiangzhong obtained approval from China's medical products regulator for its vortioxetine hydrobromide active pharmaceutical ingredient marketing application.
The API is used for the treatment of major depressive disorder in adults, according to a Monday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.